Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 -
- Ended 2019 with
- Company to host conference call and webcast today at
“On the heels of a year of significant clinical progress in 2019, we have set the pace for a robust 2020 with the advancement of our vopratelimab Phase 2 studies, the ongoing EMERGE trial and the upcoming SELECT trial. The recent announcement of the TISvopra biomarker for patient selection in SELECT is a testament to our Translational Science Platform and further emphasizes our vision of bringing the right immunotherapy to the right patients,” said
Pipeline Update and Highlights:
- Established two development paths for vopratelimab program: In early 2019, Jounce announced two development paths for vopratelimab, which are now represented by two distinct and independent Phase 2 clinical trials, EMERGE and SELECT. Both trials are based on the biology related to the pharmacodynamic biomarker, ICOS hi CD4 T cells, which emerge in the blood of patients due to vopratelimab and not PD-1 inhibitors and are associated with clinical benefit.
-- Enrollment on track in Phase 2 EMERGE trial: EMERGE trial enrollment in non-small cell lung cancer (NSCLC) remains on track, and Jounce expects to report preliminary efficacy and related biomarker data in the second half of 2020.
-- Identified the baseline TISvopra biomarker: In
February 2020, Jounce presented new data announcing the identification of the predictive biomarker associated with vopratelimab patient selection, known as TISvopra, which will be used in the upcoming SELECT trial to select patients more likely to develop ICOS hi CD4 T cells and experience clinical benefit in the presence of vopratelimab. The TISvopra biomarker is a baseline RNA signature with a threshold optimized for the prediction of the emergence of ICOS hi CD4 T cells and is expected to predict for both vopratelimab and PD-1 activity.
-- Announced trial design for upcoming Phase 2 SELECT trial: In
January 2020, Jounce announced the trial design for SELECT, a randomized, ex- U.S.trial that will evaluate vopratelimab and JTX-4014, a PD-1 inhibitor, in patients with second line, PD-1 inhibitor naive NSCLC. Jounce expects to enroll approximately 75 patients, who will be selected using the TISvopra biomarker. Jounce expects to initiate the Phase 2 SELECT trial in mid-2020 and report interim clinical data in 2021.
- Established JTX-4014 as combination agent for Phase 2 SELECT trial: Based on the results of the Phase 1 JTX-4014 trial announced in
November 2019, Jounce plans to use JTX-4014 as the PD-1 inhibitor in combination with its other product candidates beginning with the upcoming Phase 2 SELECT trial.
- Presented safety and preliminary efficacy data from Phase 1 trial at the
Society for Immunotherapyof Cancer’s (SITC) 34th Annual Meeting: In November 2019, Jounce presented safety and preliminary efficacy data from the Phase 1 trial of JTX-4014 at SITC demonstrating anti-tumor activity with an overall RECIST 1.1 response rate of 16.7% (3/18), one complete response, two partial responses and a disease control rate of 44.4% (8/18) in patients with advanced refractory solid tumor malignancies and an average of over four lines of prior therapies. JTX-4014 was found to have an acceptable safety profile in this trial.
- Named JTX-1811 as next development candidate from Translational Science Platform: In
December 2019, JTX-1811 was selected as the next development candidate to emerge from Jounce's Translational Science Platform. JTX-1811 is a monoclonal antibody designed to selectively deplete immuno-suppressive T regulatory cells. Jounce will present additional preclinical data at the 2020 American Association for Cancer Research(AACR) annual meeting and expects to file an Investigational New Drug (IND) application in the first half of 2021.
Research Collaborations and Partnerships:
- Established research collaboration with NanoString Technologies to support the application of TISvopra in Phase 2 SELECT trial: In
January 2020, Jounce entered into a new research collaboration with NanoString Technologies for the application of the TISvopra biomarker, including the optimized selection threshold in the SELECT trial. The TISvopra clinical trial assay will be implemented on the nCounter® Dx Analysis System.
- Updated strategic collaboration with Celgene Corporation: In
July 2019, Jounce and Celgene entered into a mutual agreement to terminate their broad strategic collaboration established in 2016. As a result, Jounce owns all global rights to its current pipeline, including vopratelimab, JTX-4014, JTX-1811 and all discovery-stage assets. Separately, Celgene obtained exclusive worldwide licensing rights to JTX-8064, a potential first-in-class antibody that targets the LILRB2 receptor on macrophages. Under the terms of the new license agreement, Jounce received a $50.0 millionnon-refundable license fee and is eligible to receive up to $480.0 millionfrom Celgene in development, regulatory and commercial milestone payments, as well as royalties from potential worldwide sales.
Fourth Quarter and Full Year 2019 Financial Results:
- Cash position: As of
December 31, 2019, cash, cash equivalents and investments were $170.4 million, compared to $195.9 millionas of December 31, 2018. The decrease in cash, cash equivalents and investments was primarily due to operating costs incurred during the year, offset by the $50.0 millionlicense fee received in July 2019pursuant to Jounce’s JTX-8064 license agreement with Celgene.
- License and collaboration revenue: No license and collaboration revenue was recognized during the fourth quarter of 2019, compared to
$20.1 millionfor the same period in 2018. License and collaboration revenue was $147.9 millionfor the full year 2019, compared to $65.2 millionfor the full year 2018. License and collaboration revenue recognized during 2019 was comprised of $50.0 millionof cash revenue related to Jounce’s JTX-8064 license agreement with Celgene and $97.9 millionof non-cash revenue recognition relating to the $225.0 millionupfront payment received from Celgene in July 2016. License and collaboration revenue recognized during 2018 was comprised solely of non-cash revenue recognition related to the July 2016upfront payment.
- Research and development expenses: Research and development expenses were
$16.6 millionfor both the fourth quarter of 2019 and 2018. Research and development expenses were $67.1 millionfor the full year 2019, compared to $70.1 millionfor the full year 2018. The decrease in research and development expenses for the full year 2019 was primarily due to $6.0 millionof decreased manufacturing and IND-enabling expenses as well as $0.9 millionof decreased lab consumable costs. These decreases were partially offset by $3.1 millionof increased employee compensation costs.
- General and administrative expenses: General and administrative expenses were
$6.9 millionfor the fourth quarter of 2019, compared to $6.6 millionfor the same period in 2018 and $27.9 millionfor the full year 2019, compared to $26.4 millionfor the full year 2018. The increase in general and administrative expenses for both the fourth quarter of 2019 and the full year 2019 was primarily attributable to increased employee compensation costs.
- Net (loss) income: Net loss was
$22.7 millionfor the fourth quarter of 2019, or a basic and diluted net loss per share of $0.68. Net loss was $2.0 millionfor the same period in 2018, or a basic and diluted net loss per share of $0.06. Net income was $56.8 millionfor the full year 2019, resulting in basic net income per share of $1.72and diluted net income per share of $1.66. Net loss was $27.4 millionfor the full year 2018, or a basic and diluted net loss per share of $0.84. Net income recognized for the full year 2019 was primarily attributable to $147.9 millionof license and collaboration revenue recognized under Jounce’s agreements with Celgene.
Based on its current operating and development plans, Jounce expects gross cash burn on operating expenses and capital expenditures for the full year 2020 to be approximately
Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the end of 2021.
Conference Call and Webcast Information:
nCounter® is a registered trademark of NanoString Technologies, Inc.
Cautionary Note Regarding Forward-Looking Statements:
Various statements in this release concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding financial guidance, operating expenses and capital expenditures; the timing, progress, results and release of data for clinical trials of vopratelimab and JTX-4014; identification, selection and enrollment of patients for Jounce’s clinical trials; the use of JTX-4014 in combination with Jounce’s other product candidates; and the timing, progress and results of preclinical studies for Jounce’s product candidates, including JTX-1811, and any future product candidates may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “expect,” “plan,” “on track,” “will” or similar terms, variations of such terms or the negative of those terms. Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Jounce’s ability to successfully demonstrate the efficacy and safety of its product candidates and future product candidates; the preclinical and clinical results for its product candidates, which may not support further development and marketing approval; the potential advantages of Jounce’s product candidates; Jounce’s ability to successfully manage its clinical trials; the development plans of its product candidates and any companion or complementary diagnostics; actions of regulatory agencies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Jounce’s product candidates; Jounce’s ability to obtain, maintain and protect its intellectual property; Jounce’s ability to manage operating expenses and capital expenditures; and those risks more fully discussed in the section entitled “Risk Factors” in Jounce’s most recent Annual Report on Form 10-K filed with the
|Jounce Therapeutics, Inc.|
|Consolidated Statements of Operations (unaudited)|
|(amounts in thousands, except per share data)|
|Three Months Ended
|License and collaboration revenue—related party||$||—||$||20,100||$||147,872||$||65,201|
|Research and development||16,610||16,644||67,135||70,052|
|General and administrative||6,922||6,601||27,920||26,443|
|Total operating expenses||23,532||23,245||95,055||96,495|
|Operating loss (income)||(23,532||)||(3,145||)||52,817||(31,294||)|
|Other income, net||875||1,151||4,052||3,961|
|(Loss) income before provision for income taxes||(22,657||)||(1,994||)||56,869||(27,333||)|
|Provision for income taxes||10||46||46||46|
|Net (loss) income||$||(22,667||)||$||(2,040||)||$||56,823||$||(27,379||)|
|Net (loss) income per share, basic||$||(0.68||)||$||(0.06||)||$||1.72||$||(0.84||)|
|Net (loss) income per share, diluted||$||(0.68||)||$||(0.06||)||$||1.66||$||(0.84||)|
|Weighted-average common shares outstanding, basic||33,272||32,750||33,080||32,567|
|Weighted-average common shares outstanding, diluted||33,272||32,750||34,294||32,567|
|Jounce Therapeutics, Inc.|
|Selected Consolidated Balance Sheet Data (unaudited)|
|(amounts in thousands)|
|Cash, cash equivalents and investments||$||170,444||$||195,864|
|Total deferred revenue—related party||$||—||$||97,872|
|Total stockholders’ equity||$||174,593||$||104,129|
Investor and Media Contact:
Source: Jounce Therapeutics, Inc.